3:00 p.m. Spotlight Theater B Northwest Biotherapeutics Title: Clinical development of dendritic cell‐based therapies for both resectable and unresectable tumors Abstract: Dr. Bosch will discuss NW Bio’s DCVax® platform technology, a personalized, dendritic cell based active immunotherapy for solid tumors. Unlike conventional cancer drugs and other immune therapies, which use one active agent to hit one target on the cancer, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer. NW Bio’s lead product, DCVax‐L, is designed to treat all types of operable solid tumors. DCVax‐L is currently in a 348‐patient international Phase III clinical trial for patients with newly‐diagnosed Glioblastoma multiforme brain cancer. DCVax‐L has also been applied in a Phase I trial with metastatic ovarian cancer, and in various other types of cancers in compassionate use cases. Dr. Bosch will provide updates on the clinical programs and related special access programs. NW Bio’s second product, DCVax‐Direct, is designed to treat all types of inoperable solid tumors, through intra‐tumoral injection anywhere in the body. DCVax‐Direct is being evaluated in an ongoing 60‐patient Phase I/II trial, in which more than 7 different cancers have been treated to date. Dr. Bosch will provide updates about this program and the technology involved. Speaker: Marnix Bosch
Even a Washington Post Pulitzer Prize winner called him out for his outright manipulation and childish antics. Imo company legal team keeping all records, tweets, publications, trading records, short sales and anyone assisting.
10 Million shorts plus naked shorts with no shares available. US Long hedge funds can easily double or triple their money and they know it.
The word is spreading among the educated funds and media.